Key Takeaways:
Aquestive Therapeutics Inc. (NASDAQ: AQST) is facing a securities class action lawsuit alleging the company made false and misleading statements regarding its New Drug Application for the anaphylaxis treatment Anaphylm. The lawsuit was filed on behalf of investors who purchased Aquestive securities between June 16, 2025, and January 8, 2026.
"According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose the true state of Aquestive's New Drug Application ('NDA') for Anaphylm," Rosen Law Firm said in a press release. The firm noted that Aquestive allegedly "concealed or otherwise minimized the significance of the human factors involved in the use and deployment of its sublingual film, such as packaging, use, administration, and labeling."
Law firms including Pomerantz LLP, Rosen Law Firm, and Holzer & Holzer, LLC have issued notices reminding investors of the upcoming lead plaintiff deadline. Investors who purchased AQST shares during the specified class period have until May 4, 2026, to move the court to serve as lead plaintiff in the litigation.
The lawsuit claims that when the true details regarding the Anaphylm NDA entered the market, investors suffered damages. Aquestive Therapeutics had been developing Anaphylm as a sublingual film alternative to epinephrine auto-injectors for the treatment of severe allergic reactions. The company has not yet publicly commented on the lawsuit.
This legal action introduces significant uncertainty for Aquestive Therapeutics and its shareholders. The outcome of the litigation could result in financial damages and further impact the company's stock performance. Investors will be closely watching for the company's response and any further developments in the case before the May 4 deadline.
This article is for informational purposes only and does not constitute investment advice.
